Kornimate/medical-research-clean huggingface dataset:
the effect of exposure to an informative video about amniocentesis before the procedure on maternal anxiety

Conditions: Pregnancy Related; Anxiety in Pregnancy; Amniocentesis Affecting Fetus or Newborn

Summary: the effect of exposure to an informative video about amniocentesis before the procedure on maternal anxiety

amniocentesis is a common sonography-guided procedure that is usually preformed during the second trimester of pregnancy in order to obtain neonatal genetic information. previous studies have shown that although the risk of a major complication is small, many women experience profound anxiety regarding the procedure. many stress-relieving techniques have been proposed and studied concerning stress-related interventions during pregnancy. however, the use of an informative video that is a simple, accessible, widely accepted tool has not been tested in the context of amniocentesis. in this interventional study the investigators aim to examine the effect of an informative pre-procedural video on anxiety and pain levels in women undergoing amniocentesis.

Eligibility criteria:
inclusion criteria: * women who come for amniocentesis in the edith wolfson medical center * women who sign a consent form to enroll to the study. exclusion criteria: * women under 18 years of age. * women who do not speak hebrew

Keywords: explanatory video anxiety reduction amniocentesis pregnancy
piloting an online integrated behaviour change and physical activity program

Conditions: Neurological Disorder; Behavioural Change Intervention; Physical Activity

Summary: there is a significant disparity in access to physical activity programs for people with mobility impairments, which greatly impacts mobility, function and long-term wellbeing. this study will test an online, group-based intervention consisting of exercise and behaviour activation strategies targeting these and other outcomes. importantly, this programming will be applied to patient groups across several clinical programs at parkwood institute.


Eligibility criteria:
inclusion criteria: * 18 years of age and over * neurological condition (i.e., brain injury, stroke) * completed rehabilitation and living in the community * participants must have some upper limb function permitting arm movement against gravity * physician clearance to participate in the study. exclusion criteria: * not cleared by a physician. * not able to move upper limbs against gravity. * no internet access.
physical fitness training in subacute stroke (phys-stroke)

Conditions: Stroke

Summary: the aim of this study is to investigate whether a 4-week physical fitness training (target intervention) in stroke patients (subacute stage) increase the walking speed and activities of daily living compared with a control intervention (relaxation exercises). the target or control intervention is performed in addition to standard rehabilitation treatment.


Eligibility criteria:
inclusion criteria for patients: * diagnosis of stroke within 5-45 days after stroke * age \>= 18 years * able to sit for at least 30 seconds * barthel index \< =65 at inclusion * considered able to perform aerobic exercise as determined by responsible physician * written informed consent of the patient exclusion criteria: * patient considered unable to comply with study requirements * stroke due to intracranial hemorrhage primarily due to bleeding from ruptured aneurysm or arteriovenous malformation * patients with progressive stroke * unable to perfom the required exercises due to 1. medical problems 2. musculo-skeletal problems 3. neurological problems * required help to at least 1 persons to walk before stroke due to neurological or non-neurological co-morbidities * life expectancy of less than 1 year as determined by responsible physician * alcohol or drug addiction within the last 6 months * significant current psychiatric illness as defined as medication-refractory of bipolar affective disorder, psychosis, schizophrenia or suicidality * current participation in another intervention study

Keywords: physical activity, relaxation, activities of daily living, motor functions, cognitive functions
hbv virions bound proteins

Conditions: Hepatitis B Virus Infection

Summary: the emergence of hepatocellular carcinoma (hcc) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis b virus (hbv). hbv particles acquire via budding and encapsidation cellular proteins. there is mounting evidence on several viral species that virion-bound proteins are prone to be involved either at the replication, budding/egress or entry/release steps of the viral cycle. identifying such targets may yield ideal candidates for gaining insight on the dependence of hbv upon a restricted subset of host proteins, therefore providing refined sets of genetically stable targets for therapy. this project's goals are to set up adequate conditions for robust and reproducible purification of hbv virions in clinical samples, followed by the identification of their hbv-bound host proteins and the characterization of their functions. proteomics profiling of hbv particles purified from clinical samples will be overlaid with proteins identified and characterized in cell culture grown hbv particles, using clinical biomarker discovery grade criteria. targets identified in both samples sets will be subjected to in vitro investigations using hbv-replicating cells. conventional biochemical and imaging methods will be used in order to: (i) ascertain their physical association with hbv virions; (ii) define the modalities of their interaction with hbv proteins; (iii) decipher the topology and subcellular localization of their association with hbv proteins and virions; (iv) quantitatively assess their functional involvement in particle budding, egress or secretion and infectivity. a candidate that yielded satisfactory results in these experiments will be disclosed and further investigated at the level of structural biology, in collaborative research programs.


Eligibility criteria:
inclusion criteria: * inclusion criteria * adult\> 18 and \<60 years * infected with hbv. * positive viremia for more than 6 months * viremia\> 106 iu / ml. * immunotolerant individuals, untreated * aviraemic individuals, exclusion criteria: * patient with against-indication for a blood sample of 150 ml * immunosuppressive therapy patient * patient with liver disease other than hepatitis b. * patient with hepatocellular carcinoma. * patients with one or more severe co-morbidities defined as: * co-infection with hiv or hepatitis c virus (hcv). * hematological malignancies changing or aplasia * insulin-dependent diabetes * dialyzed chronic renal failure * heart failure * persons subject to legal protection or the subject of a safeguard measure of justice * not affiliated with a social security scheme or not beneficiaries of such a scheme * pregnant women

Keywords: hbv liver
infusion laboratory: protocol 5 (flupenthixol) - 14

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol, to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol modifies the subjective as well as physiological effects of cocaine. taken together, these relatively d-1 selective agents can help determine the extent to which da-1 binding affects the reinforcing effects of stimulants.


Eligibility criteria:
inclusion criteria: m/f, ages 21-50. meet dsm-iv criteria for cocaine dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: cocaine dependence
safety and efficacy of house dust mite allergen extract in the treatment of allergic rhinoconjunctivitis

Conditions: House Dust Mite Allergy

Summary: the trial is performed to assess efficacy and safety of novo-helisen depot in allergic rhinoconjunctivitis


Eligibility criteria:
inclusion criteria: * positive skin prick test to house dust mite, * positive rast test to house dust mite, * positive provocation test result to house dust mite, exclusion criteria: * serious chronic diseases, * other perennial allergies

Keywords: house dust mite, allergy
the role of a mediterranean diet in patients with endometriosis: a feasibility trial

Conditions: Endometriosis

Summary: this study aims to test if making changes to diet can affect the pelvic pain associated with endometriosis. one group will follow a mediterranean diet for 12 weeks while the control group will continue with their current diet. we will be looking at the feasibility of a larger-scale trial as well as self-reported quality of life and self-reported pain using standardized questionnaires, that have previously been used and validated, and assessing how this diet affects biomarkers associated with endometriosis and inflammation. further, we will test how this change in diet affects the gut microbe flora.


Eligibility criteria:
inclusion criteria: * identified female at birth * aged 18-45 * diagnosed with endometriosis (radiologically (ultrasound or magnetic resonance imaging (mri)) or surgically confirmed diagnosis of endometriosis) * able and willing to provide written consent to participate in the study. exclusion criteria: * history of or diagnosis of gynecologic or gi malignancy * post-menopausal * currently pregnant or lactating * dietary restrictions due to medical conditions (e.g., celiac disease, allergies) * people who are already following a formal anti-inflammatory diet.

Keywords: diet modification anti-inflammatory diet endometriosis diet
adverse events during upper gastrointestinal endoscopy

Conditions: Patients Need Upper Gastrointestinal Endoscopy; Peptic Ulcer; Gastric Cancer; Esophagus Cancer; Oesophagitis

Summary: the primary objective is to investigate the adverse events during upper gastrointestinal endoscopy with and without sedation in chinese population


Eligibility criteria:
inclusion criteria: * patients will undergo upper gastrointestinal endoscopy * age \> 18 years old * signed informed consent form exclusion criteria: * pregnant * allergy to propofol or soybean or albumen

Keywords: adverse events upper gastrointestinal endoscopy sedation
safety and efficacy study of intravenous lidocaine after colorectal surgery: lidorehab

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to check if lidocaine intravenous administration during surgery and 24 hours after surgery, associated with standardised management of the patient, helps to accelerate recovery and to improve the quality of recovery, after surgery for colic or rectal neoplasms.

one of the purposes of postoperative care is to shorten the duration of recovery, in order to reduce the complications and to improve the quality of life. after abdominal surgery, two factors can be modified: early mobilisation, thanks to optimal pain control, and return to a normal feeding, permitted by transit recovery. opioids, which are usually used for pain control, delay the intestinal transit and can be responsible for side effects like drowsiness, nausea, urine retention. lidocaine is a local anaesthetic, which means that it can stop the pain if it is administrated around the nerves. it can also be used intravenously. in this way, it is supposed to decrease opioid consumption, accelerate intestinal transit and even decrease inflammation. side effects of lidocaine appear at higher plasma concentrations than those considered in the study. after randomisation, the patient will receive either intravenous lidocaine during the surgery and 24 hours after the surgery, or physiological serum (like placebo). every patient will dispose of patient-controlled-analgesia with morphine and of a standardised care management. data will be collected concerning pain level, morphine consumption, psychomotor performances, duration of ileus, speed of activity recovery, quality of recovery, and side effects. biological evaluation of lidocaine concentration and inflammation will also be done.

Eligibility criteria:
inclusion criteria: * colorectal neoplasm * radical surgery * median incision exclusion criteria: * american society of anesthesiologists (asa) score equal to or up to 3 * unwilling or unable to use patient-controlled analgesia (pca) * chronic consumption of opioids * chronic drug or alcohol abuse * chronic pain * unable to read or write text * inflammatory disease of intestinal tract * allergy to morphine * allergy to lidocaine * severe atrioventricular conduction dysfunction without stimulator * porphyry * uncontrolled epilepsy * history of malign hyperthermia * severe cardiac failure * hepatic failure * myasthenia * treatment with beta blockers, antiarrhythmic calcium blockers, sultopride, nonselective monoamine oxidase inhibitor (maoi) * locoregional anaesthesia planned * associated surgery concerning liver, pancreas, or gall bladder * laparoscopic surgery * severe psychiatric pathology * refusal of the patient

Keywords: double blind method prospective study lidocaine/administration and dosage/therapeutic use anaesthetics local/administration and dosage opioids/administration and dosage pain, postoperative perioperative care postoperative care analgesia, patient-controlled length of stay survival analysis patient satisfaction surgery middle age adult aged
empirical antibiotic and outcome in community-onset bacteremia

Conditions: Bacteremia

Summary: empirical antibiotic and outcome in community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae

prospective cohort study is conducted for monitoring outcomes and risk factors among community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae. primary endpoint is mortality rate among those who received initially inappropriate antimicrobial which switch to appropriate antimicrobial later when culture and antimicrobial susceptibility test reported among community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae.

Eligibility criteria:
inclusion criteria: * patient with community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae. age \> 18 years exclusion criteria: * pregnancy * polymicrobial infection
everolimus stent in patients with coronary artery disease (cad)

Conditions: Coronary Artery Disease; Coronary Atherosclerosis

Summary: aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers pci eligible patients

compared with the currently available first-generation drug-eluting stents (des), second-generation des have been designed with the goal of improving safety and efficacy. everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. a significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. sirolimus eluting stent was the first available drug eluting stent and is the most tested. therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.

Eligibility criteria:
inclusion criteria: * all patients with coronary artery disease eligible for percutaneous coronary intervention (pci) exclusion criteria: * contraindication to dual antiplatelet therapy for 12 months * known allergy to sirolimus or everolimus * major surgical procedure planned within 1 month * history, symptoms, or findings suggestive of aortic dissection. * participation in other trials * pregnancy

Keywords: drug eluting stents everolimus eluting stent coronary angioplasty
oxaliplatin and docetaxel followed by cetuximab for head and neck cancer

Conditions: Head and Neck Cancer; Carcinoma, Squamous

Summary: a study of oxaliplatin and docetaxel followed by cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size

this is a non-randomized, open-label, phase ii study to assess the effects of oxaliplatin and docetaxel followed by epidermal factor-antibody (egfr-ab) cetuximab on patients with previously treated recurrent /metastatic squamous cell carcinoma of the head and neck. head and neck tissue will also be tested to determine if the protein epidermal growth factor receptor is present in the cancer cells.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed recurrent scchn * 18 years or older * tumor site accessible by biopsy * measurable disease * receiving no other therapy * ecog performance status 0-1 * adequate bone marrow, renal function and hepatic function exclusion criteria: * active infection or fever within 3 days of treatment * active cns metastases * prior malignancy within 5 years * hypersensitivity to study drugs * chemotherapy within 30 days of treatment * concurrent investigational therapy within 30 days * radiotherapy of more than 25% of bone marrow * peripheral neuropathy of grade 2 or greater * pregnant or lactating patients * history of allogeneic transplant * active or previously treated hiv or hepatitis b or c * patients with a tracheostomy

Keywords: cancer head and neck cancer squamous cell cancer
natural history study of batten disease

Conditions: Batten Disease; Neuronal Ceroid Lipofuscinosis CLN6; Neuronal Ceroid Lipofuscinosis CLN3

Summary: this is a multicenter, international, study to assess the natural history data from people with batten disease by collecting both retrospective and prospective information about the motor, behavioral and functional capabilities of patients. the study initially has 2 cohorts. cohort 1 (n ≈ 75) includes subjects with cln6 batten disease. cohort 2 (n ≈ 120) includes subjects with juvenile cln3 batten disease. additional cohorts for other batten disease subtypes may be added in the future.


Eligibility criteria:
inclusion criteria: * subject has or had a diagnosis of cln6 or cln3 batten disease that has been confirmed by genotyping (documented presence of a variant on both gene alleles). confirmation of genotyping will be performed prior to enrollment. * subject (or legally authorized representative) has provided written informed consent (or assent) and authorization for use and disclosure of personal health information or research related health information * subjects may enroll starting from birth exclusion criteria: * subject has or had experienced another illness that is known to cause cognitive decline (eg, trauma, meningitis, hemorrhage) * subject received or receives an investigational gene therapy

Keywords: neuronal ceroid lipofuscinosis (ncl) cln6 vlincl6 cln6 batten disease batten disease cln3 cln3 batten disease variant late infantile
a comparison of recombinant human brain natriuretic peptide and dobutamine

Conditions: Acute Decompensated Heart Failure

Summary: to compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhbnp) with dobutamine on acute decompensated heart failure patients with different blood bnp levels

patients with acute decompensated heart failure (adhf) whose left ventricular ejection fraction(lvef) was \ 3000 pg/ml) , depending on their admission plasma bnp levels. each group was then subdivided into rhbnp or dobutamine subgroups according to intravenous administration with either rhbnp or dobutamine for 24-72h. the effects of rhbnp and dobutamine on patients in the high and extra-high bnp groups were compared.

Eligibility criteria:
inclusion criteria: * patients were classified as nyha class iii-iv * ejection fraction \<40% exclusion criteria: * intravenous administration with rhbnp or dobutamine in the 2 weeks before study entry * acute myocardial infarction * significant valvular stenosis * serious ventricular arrhythmia (frequent ventricular premature beat of \>5 bpm, nonsustained and sustained ventricular tachycardia) * blood pressure \ 140/90 mmhg * shock * hypovolemia * hepatic or renal impairment * pregnant and lactating women.

Keywords: heart failure rhbnp dobutamine
daily routines, executive functioning & adhd

Conditions: Attention Deficit Disorder with Hyperactivity (ADHD)

Summary: the goal of this clinical trial is to learn adjusting daily or nightly routines improves executive functioning in youth with adhd. it will also learn about the acceptability of the intervention. the main questions it aims to answer are: 1. does the intervention improve sleep for youth with adhd? 2. does the intervention improve areas of executive functioning for youth with adhd? 3. is this an acceptable intervention for youth with adhd? researchers will compare the two intervention conditions to see if their are impacts in executive functioning and sleep. participants will: complete cognitive testing, executive function tasks, questionnaires, and an interview at baseline and at one month wear an actigraph watch for one month bring a parent with them to three meetings complete daily sleep diaries for one month

the purpose of this study will be to examine if adolescents with adhd with altered daily or nightly routines show improvements in ef, specifically working memory, cognitive flexibility, and inhibitory control. this will be a pilot study including up to 25 adolescents between the ages of 11 and 17 years old, with a diagnosis of adhd (combined presentation, or predominantly inattentive presentation). participants will be stratified by gender and randomly assigned to one of two conditions: 1) night routines or 2) daily routines. the intervention is ready to be implemented and adapted for an adhd population. though the intervention itself was not focused on sleep hygiene, the team incorporated strategies to increase the likelihood of extending sleep duration, such as reviewing actigraphy and sleep diary data with the participant, collaboration between the participant, caregiver and researcher to address obstacles to obtaining enough sleep, and instructing the participant to obtain a specific amount of sleep. the first study demonstrated that sleep extension in youth with type 1 diabetes (t1dm) was feasible, whereas the ongoing study has demonstrated that overall youth increase tst over a 3-month period. this latter study has a booster session approximately one month after the initial consultation. thus, this study will last one month with two weeks of baseline to establish sleep patterns and the intervention portion for this study will last for two weeks to monitor whether the youth increase their sleep and ascertain an effect size of intervention impact.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of attention-deficit/hyperactivity disorder (adhd) * located in the greater tucson, az area * must have a guardian willing to participate exclusion criteria: * clinical diagnosis of autism spectrum disorder * clinical diagnosis of an intellectual disability * clinical diagnosis of psychosis * clinical diagnosis of bipolar disorder

Keywords: adhd executive function attention adolescent working memory